구조모아 (StructureMoa)항암 chemical structure spider web
방문분석
큐레이션 브리핑
anti-VEGF (aflibercept). wet AMD·DME. Lucentis·Vabysmo와 BCVA·주기·dual-target 전략.
Intravitreal VEGF Trap (aflibercept) fusion protein neutralizing VEGF-A, VEGF-B, and PlGF; leading wet AMD / DME anti-VEGF.
기전. Aflibercept acts as a soluble decoy receptor binding VEGF-A, VEGF-B, and PlGF with higher affinity than native VEGFR, preventing activation of VEGFR1/2 and reducing pathological angiogenesis and vascular permeability in the retina.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
VEGF-A / VEGF-B / PIGF
Wet AMD, DME, RVO, diabetic retinopathy
US, EU, JP
Approved
eylea · aflibercept · Eylea · Zaltrap · Eylea HD
2026-09-10
Data Confidence · High
Development Signal · Established
bispecific antibody targeting both VEGF-A and angiopoietin-2, has emer
unique records
구조화 데이터
unique records
Tachyphylaxis, fibrosis, and need for shorter dosing intervals in subset of patients.
bispecific antibody targeting both VEGF-A and angiopoietin-2, has emer
VEGF-A / VEGF-B / PIGF · biomarkers can reliably diagnose and monitor PCV, restricting the role of invasive indocyanine green angiogra
Aflibercept acts as a soluble decoy receptor binding VEGF-A, VEGF-B, and PlGF with higher affinity than native VEGFR, preventing activation of VEGFR1/2 and reducing pathological angiogenesis and vascular permeability in the retina.
apoptosis, and VEGF-A levels were evaluated using confocal microscopy, plate reader-based assays, and ELISA techniques
biomarkers can reliably diagnose and monitor PCV, restricting the role of invasive indocyanine green angiogra
Tachyphylaxis, fibrosis, and need for shorter dosing intervals in subset of patients.
구조화 데이터
mouse
Extended intravitreal half-life vs Fab fragments (~4–6 days vitreal, sustained biologic effect q4–8w)
CST reduction, BCVA gain
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
구조화 데이터
ClinicalTrials.gov에 등록된 완료 예정일입니다. 추정이며 결과 발표를 단정하지 않습니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
분석
큐레이션 브리핑
anti-VEGF (aflibercept). wet AMD·DME. Lucentis·Vabysmo와 BCVA·주기·dual-target 전략.
Intravitreal VEGF Trap (aflibercept) fusion protein neutralizing VEGF-A, VEGF-B, and PlGF; leading wet AMD / DME anti-VEGF.
기전. Aflibercept acts as a soluble decoy receptor binding VEGF-A, VEGF-B, and PlGF with higher affinity than native VEGFR, preventing activation of VEGFR1/2 and reducing pathological angiogenesis and vascular permeability in the retina.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
VEGF-A / VEGF-B / PIGF
Wet AMD, DME, RVO, diabetic retinopathy
US, EU, JP
Approved
eylea · aflibercept · Eylea · Zaltrap · Eylea HD
2026-09-10
Data Confidence · High
Development Signal · Established
bispecific antibody targeting both VEGF-A and angiopoietin-2, has emer
unique records
구조화 데이터
unique records
Tachyphylaxis, fibrosis, and need for shorter dosing intervals in subset of patients.
bispecific antibody targeting both VEGF-A and angiopoietin-2, has emer
VEGF-A / VEGF-B / PIGF · biomarkers can reliably diagnose and monitor PCV, restricting the role of invasive indocyanine green angiogra
Aflibercept acts as a soluble decoy receptor binding VEGF-A, VEGF-B, and PlGF with higher affinity than native VEGFR, preventing activation of VEGFR1/2 and reducing pathological angiogenesis and vascular permeability in the retina.
apoptosis, and VEGF-A levels were evaluated using confocal microscopy, plate reader-based assays, and ELISA techniques
biomarkers can reliably diagnose and monitor PCV, restricting the role of invasive indocyanine green angiogra
Tachyphylaxis, fibrosis, and need for shorter dosing intervals in subset of patients.
구조화 데이터
mouse
Extended intravitreal half-life vs Fab fragments (~4–6 days vitreal, sustained biologic effect q4–8w)
CST reduction, BCVA gain
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
구조화 데이터
ClinicalTrials.gov에 등록된 완료 예정일입니다. 추정이며 결과 발표를 단정하지 않습니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.